BCCO.Y Stock Overview
Operates as a bioconvergence company in North America, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BICO Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.19 |
| 52 Week High | SEK 1.55 |
| 52 Week Low | SEK 0.98 |
| Beta | 2.36 |
| 11 Month Change | 13.33% |
| 3 Month Change | n/a |
| 1 Year Change | 51.44% |
| 33 Year Change | -91.96% |
| 5 Year Change | n/a |
| Change since IPO | -91.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| BCCO.Y | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 13.3% | -0.7% | 0.6% |
| 1Y | 51.4% | 13.3% | 32.1% |
Return vs Industry: BCCO.Y exceeded the US Life Sciences industry which returned 10% over the past year.
Return vs Market: BCCO.Y exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| BCCO.Y volatility | |
|---|---|
| BCCO.Y Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BCCO.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BCCO.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 832 | Maria Forss | www.bico.com |
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing.
BICO Group AB (publ) Fundamentals Summary
| BCCO.Y fundamental statistics | |
|---|---|
| Market cap | US$299.56m |
| Earnings (TTM) | -US$148.18m |
| Revenue (TTM) | US$239.66m |
1.2x
P/S Ratio-2.0x
P/E RatioIs BCCO.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCCO.Y income statement (TTM) | |
|---|---|
| Revenue | SEK 2.42b |
| Cost of Revenue | SEK 684.50m |
| Gross Profit | SEK 1.74b |
| Other Expenses | SEK 3.24b |
| Earnings | -SEK 1.50b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -21.23 |
| Gross Margin | 71.75% |
| Net Profit Margin | -61.83% |
| Debt/Equity Ratio | 48.6% |
How did BCCO.Y perform over the long term?
See historical performance and comparison